Wegovy

Wegovy is a prescription medicine brand owned by the Danish pharmaceutical company Novo Nordisk. Its active ingredient is semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that the same company markets under the Ozempic brand for type 2 diabetes and under Rybelsus as an oral tablet. Wegovy is specifically the 2.4 mg once-weekly subcutaneous injection version approved for chronic weight management in adults with obesity or overweight plus at least one weight-related condition, and later for reducing major adverse cardiovascular events in adults with established cardiovascular disease and excess weight. The brand was launched in the United States in June 2021 after FDA approval, becoming the first GLP-1 receptor agonist specifically approved for chronic weight management since 2014. It was subsequently approved in the United Kingdom, the European Union, Japan, Canada, Australia and other markets. In 2024 the FDA also approved a 2.4 mg maintenance dose for adolescents, and in 2025 Novo Nordisk introduced an oral semaglutide 25 mg version under the Wegovy brand in the United States. Wegovy is positioned as a chronic-disease therapy rather than a cosmetic weight-loss product, with clinical data from the STEP and SELECT trials showing average weight reductions of roughly 15% and a 20% reduction in major cardiovascular events. Supply constraints, high list prices, insurance coverage disputes and compounded alternatives have shaped its commercial story. Novo Nordisk manufactures the drug at sites in Denmark and the United States and has invested heavily in expanding fill-finish capacity. The brand competes primarily with Eli Lilly's tirzepatide products, Zepbound for weight management and Mounjaro for diabetes. Novo Nordisk reports Wegovy sales within its obesity-care franchise, which has become one of the company's fastest-growing revenue lines and a major driver of its market valuation.

Wegovy's history is inseparable from the development of semaglutide by Novo Nordisk. Semaglutide was first approved as Ozempic for type 2 diabetes in 2017 and as Rybelsus oral tablets in 2019. The weight-management potential of GLP-1 receptor agonists had been demonstrated by earlier liraglutide (Saxenda), but semaglutide showed substantially greater efficacy in the STEP clinical programme. In June 2021 the U.S. Food and Drug Administration approved Wegovy (semaglutide 2.4 mg injection) for chronic weight management in adults with obesity or overweight with at least one weight-related condition. It was the first new drug approved for this indication since 2014. Launch was complicated by manufacturing constraints, and Novo Nordisk temporarily restricted supply of the starting doses in the United States in 2022 to protect existing patients. Regulatory approvals followed in the United Kingdom, the European Union, Japan, Canada and other markets. In 2023 Novo Nordisk initiated the SELECT cardiovascular outcomes trial, and in March 2024 the FDA approved a label expansion for Wegovy to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight. In 2024 the FDA also approved Wegovy for adolescents aged 12 and older with obesity. In 2025 Novo Nordisk introduced an oral semaglutide 25 mg product under the Wegovy brand in the United States, extending the franchise beyond injectables. The brand faces intense competition from Eli Lilly's tirzepatide (Zepbound/Mounjaro), pricing pressure from pharmacy benefit managers, and the emergence of compounded semaglutide during supply shortages. Novo Nordisk has responded with direct-to-consumer pharmacy partnerships and price reductions in some markets.

• FDA approves Wegovy (semaglutide 2.4 mg) for chronic weight management.

• Novo Nordisk restricts supply of lower Wegovy doses in the U.S. due to manufacturing constraints.

• SELECT cardiovascular outcomes trial results announced, showing 20% risk reduction.

• FDA approves Wegovy label expansion for cardiovascular risk reduction.

• FDA approves Wegovy for adolescents aged 12 and older with obesity.

• Oral semaglutide 25 mg launched under the Wegovy brand in the U.S.

Prescription chronic weight management and cardiovascular risk reduction therapy; premium GLP-1 obesity-care brand.

• Wegovy injection 2.4 mg

  Once-weekly subcutaneous semaglutide pen for chronic weight management.

• Wegovy oral tablets 25 mg

  Once-daily oral semaglutide for chronic weight management.

• 2026-01-05

  Novo Nordisk launches once-daily Wegovy weight-loss pill in the US[5]诺和诺德在美国推出每日一次Wegovy减肥药片wsbtv.com

  Reported: 2026-01-05

  Novo Nordisk launched the once-daily pill version of its weight-loss drug Wegovy in the United States on Monday, following FDA approval in December 2025. The pill is priced at $199-$299 per month and will be sold through US pharmacies including Costco and CVS and telehealth providers such as Ro, LifeMD, WeightWatchers, GoodRx and NovoCare Pharmacy.

  Weekdays and relative dates follow the original report; their exact calendar dates have not been verified.

• 2021-06-04

  FDA approves Wegovy for chronic weight management[6]FDA 批准 Wegovy 用于长期体重管理finanznachrichten.de

  Reported: 2021-06-04

  The U.S. Food and Drug Administration approved Wegovy, a higher-dose version of semaglutide, for chronic weight management in adults with obesity or overweight who meet the stated criteria.

1. 1Wegovy official websitewegovy.com
2. 2Novo Nordisk Wegovy product pagenovonordisk.com
3. 3FDA approves Wegovy for chronic weight managementfda.gov
4. 4FDA approves Wegovy for cardiovascular risk reductionfda.gov
5. 5诺和诺德在美国推出每日一次Wegovy减肥药片wsbtv.com
6. 6FDA 批准 Wegovy 用于长期体重管理finanznachrichten.de
7. 7Novo Nordisk launches once-daily Wegovy weight-loss pill in the US; cost ranges from $199-$299 a month | Company Business Newslivemint.com